IL17A and Sepsis: In response to procalcitonin neutralizing antibody exposition but also receptor blockade and inhibition of procalcitonin activation, we observed a marked reduction of IL-17A in septic mice plasma, suggesting that inhibition of IL-17 signaling is an additional mechanisms of the beneficial effects of antagonizing procalcitonins action during sepsis.